The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Responses to drugs and pharmacological treatments differ considerably between individuals. Importantly, only 50%–75% of patients have been shown to react adequately to pharmacological interventions, whereas the others experience either a lack of efficacy or suffer from adverse events. The liver is of central importance in the metabolism of most drugs. Because of this exposed status, hepatotoxicity is amongst the most common adverse drug reactions and hepatic liabilities are the most prevalent reason for the termination of development programs of novel drug candidates. In recent years, more and more factors were unveiled that shape hepatic drug responses and thus underlie the observed inter-individual variability. In this review, we provide a comprehensive overview of different principle mechanisms of drug hepatotoxicity and illustrate how patient-specific factors, such as genetic, physiological and environmental factors, can shape drug responses. Furthermore, we highlight other parameters, such as concomitantly prescribed medications or liver diseases and how they modulate drug toxicity, pharmacokinetics and dynamics. Finally, we discuss recent progress in the field of in vitro toxicity models and evaluate their utility in reflecting patient-specific factors to study inter-individual differences in drug response and toxicity, as this understanding is necessary to pave the way for a patient-adjusted medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Evolution and functional impact of rare coding variation from deep sequencing of human exomes
Tennessen, J. A., Bigham, A. W., O’Connor, T. D., Fu, W., Kenny, E. E., Gravel, S., McGee, S., Do, R., Liu, X., Jun, G., et al. (2012) · Science · doi:10.1126/science.1219240 · Cited by 1,613
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07873-x · Cited by 1,380
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
The UK10K project identifies rare variants in health and disease
The UK10K Consortium, Writing group, Walter, K., Min, J. L., Huang, J., Crooks, L., Memari, Y., McCarthy, S., Perry, J. R. B., Xu, C., et al. (2015) · Nature · doi:10.1038/nature14962 · Cited by 1,040
Timing of new black box warnings and withdrawals for prescription medications
Lasser, K. E. (2002) · JAMA · doi:10.1001/jama.287.17.2215 · Cited by 1,005
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation
Dominguez, A. A., Lim, W. A., & Qi, L. S. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.2 · Cited by 832
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Self-citationLonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3ef9c · Cited by 624
McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331702 · Cited by 616
Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P. (2011) · JAMA · doi:10.1001/jama.2011.1880 · Cited by 472
Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
Murphy, S. K., Yang, H., Moylan, C. A., Pang, H., Dellinger, A., Abdelmalek, M. F., Garrett, M. E., Ashley–Koch, A., Suzuki, A., Tillmann, H. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.047 · Cited by 391
Michael, S. L., Pumford, N. R., Mayeux, P. R., Niesman, M. R., & Hinson, J. A. (1999) · Hepatology · doi:10.1002/hep.510300104 · Cited by 335
Multi-cell type human liver microtissues for hepatotoxicity testing
Messner, S., Agarkova, I., Moritz, W., & Kelm, J. M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0968-2 · Cited by 319
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Treyer, A., & Müsch, A. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120009 · Cited by 252
Visualizing Human Leukocyte Antigen Class II Risk Haplotypes in Human Systemic Lupus Erythematosus
Graham, R. R., Ortmann, W. A., Langefeld, C. D., Jawaheer, D., Selby, S. A., Rodine, P. R., Baechler, E. C., Rohlf, K. E., Shark, K. B., Espe, K. J., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342290 · Cited by 223
Competency of different cell models to predict human hepatotoxic drugs
Gómez-Lechón, M. J., Tolosa, L., Conde, I., & Donato, M. T. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967680 · Cited by 199
The costs of adverse drug events in community hospitals
Hug, B. L., Keohane, C., Seger, D. L., Yoon, C., & Bates, D. W. (2012) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(12)38016-1 · Cited by 169
Heslop, J. A., Rowe, C., Walsh, J., Sison-Young, R., Jenkins, R., Kamalian, L., Kia, R., Hay, D., Jones, R. P., Malik, H. Z., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-016-1694-y · Cited by 141
Proteome-Wide Analyses of Human Hepatocytes During Differentiation and Dedifferentiation
Rowe, C., Gerrard, D. T., Jenkins, R., Berry, A., Durkin, K., Sundstrom, L., Goldring, C. E., Park, K. B., Kitteringham, N. R., Hanley, K. P., et al. (2013) · Hepatology · doi:10.1002/hep.26414 · Cited by 133
Barcellos, L. F., May, S. L., Ramsay, P. P., Quach, H. L., Lane, J. A., Nititham, J., Noble, J. A., Taylor, K. E., Quach, D. L., Chung, S. A., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000696 · Cited by 131
Lauschke, V. M., Vorrink, S. U., Moro, S. M. L., Rezayee, F., Nordling, Å., Hendriks, D. F. G., Bell, C. C., Sison‐Young, R., Park, B. K., Goldring, C. E., et al. (2016) · Hepatology · doi:10.1002/hep.28780 · Cited by 121
Self-citation
Cited by
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Self-citationAndrade, J. G., Aguilar, M., Atzema, C., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 562
Bell, C. C., Dankers, A. C. A., Lauschke, V. M., Sison-Young, R., Jenkins, R., Rowe, C., Goldring, C. E., Park, K., Regan, S. L., Walker, T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx289 · Cited by 327
Self-citationBell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Self-citation
Metadata
- Authors
- Lauschke, V., & Ingelman-Sundberg, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-10-12
- Volume
- 17
- Issue
- 10
- Pages
- 1714
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2530165814
- Cited by
- 88
- References
- 26
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.